Skip to content
Peptide research

Argireline

Also known as Acetyl Hexapeptide-8
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A synthetic hexapeptide sold in cosmetic serums as a needle-free alternative to botulinum toxin for crow's feet and expression lines. Human evidence for modest wrinkle reduction is moderate and tolerability looks favorable, but efficacy is inconsistent, skin penetration is doubtful given the peptide's size, and claims it rivals botox are speculative. It is a cosmetic ingredient, not an approved drug, carries no FDA approval, and purity varies among products.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Reduction of expression wrinkles (crow's feet, forehead lines, periorbital wrinkles)

    Medium

    A small human RCT showed significant wrinkle reduction versus placebo, but replication is lacking.

  • Non-invasive alternative to botulinum toxin injections

    Speculative

    No head-to-head human trials exist; topical form does not reach facial muscle tissue.

  • Favorable safety and tolerability profile

    Medium

    Small human studies report good tolerability at low concentrations, with no serious adverse events.

Evidence limits

Evidence Level
Moderate

Clinical evidence for Argireline is mixed. Early studies used subjective ratings and objective skin-replica measurements. The 2013 RCT reported a 48.9% subjective response rate and improved objective roughness measures. However, a more recent study using objective Visia imaging found no statistically significant effect attributable to Argireline specifically (both sides received hyaluronic acid serum, and neither within-side improvement was statistically significant). The fundamental limitation is extremely poor skin penetration (<0.2% in 24 hours), which raises questions about whether bioactive concentrations reach neuromuscular targets. Safety evidence is consistently strong across all studies.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Minimal skin penetration

    High
  • Mild local irritation

    Low
  • Injection-related adverse events

    Moderate
  • Inconsistent clinical efficacy

    High
  • Potential for exaggerated marketing claims

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.